About NeuroDawn
NeuroDawn was a Healthcare company based in China founded in 2021. It develops innovative therapeutic technologies for central nervous system diseases. It operates on a B2B model. NeuroDawn has raised $10.76 million across 1 funding round from investors including Simcere Pharma, 2Y-Chem and Balancing Capital. The company is recorded as dissolved. Its focus areas include Biotechnology, Therapeutics and CNS Diseases.
Company details
NeuroDawn, established in 2021, excels in providing healthcare solutions, advancing biotech innovations, therapeutics, and cns diseases. Develops innovative therapeutic technologies for central nervous system diseases. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
- Headquarters China
- SectorsHealthcare
- Website neurondawn.com
- Total Equity Funding$10.76M (USD)
in 1 rounds
- Latest Funding Round$10.76M (USD), Series A
Aug 2021
- InvestorsSimcere Pharma
& 2 more
Funding Insights of NeuroDawn
NeuroDawn has successfully raised a total of $10.76M through 1 strategic funding round. The most recent funding activity was a Series A round of $10.76 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10.76M
- Total Rounds 1
- Last Round Series A — $10.76M
- First Round $10.76M
(Aug 2021)
- Investors Count 3
All 1 funding rounds of NeuroDawn with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2021 | $10.76M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in NeuroDawn
NeuroDawn has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Simcere Pharma, 2Y-Chem and Balancing Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Novel oncology and immunology therapeutics are developed and commercialized. | 1995 | simcere.com | Nanjing, China | |
Specializes as a CDMO for manufacturing API products in the biopharma sector. | 2003 | 2ychem.com | Shanghai, China | |
Manages a real estate fund with diverse investment strategies for optimal returns. | 2018 | balancecapitals.com | Seattle, United States |
Investor details for NeuroDawn
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of NeuroDawn
2 dated milestones of NeuroDawn, from founding to its latest funding, stage changes and deals.
- Founded NeuroDawn is founded.
- Funding First funding round of $10.8M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neurodawn
Complete news archive for NeuroDawn
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NeuroDawn
NeuroDawn was founded in 2021.
NeuroDawn is headquartered in China.
NeuroDawn is a funded company, having raised a total of $10.76M across 1 funding round to date. The company's 1st funding round was a Series A of $10.76M, raised on Aug 2021.
NeuroDawn, established in 2021, excels in providing healthcare solutions, advancing biotech innovations, therapeutics, and cns diseases. Develops innovative therapeutic technologies for central nervous system diseases. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
NeuroDawn has 3 investors. Key investors include Simcere Pharma, 2Y-Chem, and Balancing Capital.